Incidence, clinical presentation, and outcome of hiv-1-associated cryptococcal meningitis during the highly active antiretroviral therapy era: A nationwide cohort study

Madeleine Touma, Line D. Rasmussen, Raquel Martin-Iguacel, Frederik Neess Engsig, Nina Breinholt Stærke, Mette Stærkind, Niels Obel, Magnus Glindvad Ahlström*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

212 Downloads (Pure)

Abstract

Background: Human immunodeficiency virus (HIV) infection with advanced immunosup-pression predisposes to cryptococcal meningitis (CM). We describe the incidence, clinical presentation, and outcome of CM in HIV-infected individuals during the highly active antiretroviral therapy (HAART) era. Methods: A nationwide, population-based cohort of HIV-infected individuals was used to estimate incidence and mortality of CM including risk factors. A description of neurological symptoms of CM at presentation and follow-up in the study period 1995–2014 was included in this study. Results: Among 6,351 HIV-infected individuals, 40 were diagnosed with CM. The incidence rates were 3.7, 1.8, and 0.3 per 1000 person-years at risk in 1995–1996, 1997–1999, and 2000–2014, respectively. Initiation of HAART was associated with decreased risk of acquiring CM [incidence rate ratio (IRR), 0.1 (95% CI, 0.05–0.22)]. African origin was associated with increased risk of CM [IRR, 2.05 (95% CI, 1.00–4.20)]. The main signs and symptoms at presentation were headache, cognitive deficits, fever, neck stiffness, nausea, and vomiting. All individuals diagnosed with CM had a CD4 + cell count <200 cells/µl [median 26; interquartile range (IQR), 10–50)]. Overall, mortality following CM was high and mortality in the first 4 months has not changed substantially over time. However, individuals who survived generally had a favorable prognosis, with 86% (18/21) returning to the pre-CM level of activity. Conclusion: The incidence of HIV-associated CM has decreased substantially after the introduction of HAART. To further decrease CM incidence and associated mortality, early HIV diagnosis and HAART initiation seems crucial.

Original languageEnglish
JournalClinical Epidemiology
Volume9
Pages (from-to)385-392
ISSN1179-1349
DOIs
Publication statusPublished - 2017

Keywords

  • Cryptococcal meningitis
  • Highly active antiretroviral therapy
  • HIV

Fingerprint

Dive into the research topics of 'Incidence, clinical presentation, and outcome of hiv-1-associated cryptococcal meningitis during the highly active antiretroviral therapy era: A nationwide cohort study'. Together they form a unique fingerprint.

Cite this